Those living with diabetes who don't have insurance will pay $35 for a 30-day supply of Sanofi U.S. insulins.
In efforts to address the affordability and access issues for diabetes insulin, Optum, a UnitedHealth Group organization, is partnering with Sanofi to offer a 30-day supply of commonly used Sanofi insulins for $35 to those with diabetes and without insurance. Folks can purchase their Optum-Sanofi insulin through its online health services and products retailer Optum Store.
Now available with a valid prescription, the new, lower-cost insulin solution accelerates UnitedHealth Group’s ongoing effort to ensure people get the prescription medications they need and make healthcare more affordable.
People can access the Optum Store to determine whether their insulin is part of the affordability program, get qualified and download an insulin savings card, and then fill their prescription at the $35 price point at any retail pharmacy. A mail-service option will soon be available for people who prefer home delivery through the Optum Store.
Last month, UnitedHealthcare announced plans to eliminate out-of-pocket costs in standard fully insured group plans for certain preferred prescription drugs, including insulin and several drugs used to treat emergencies.
“The need for affordable insulin is urgent, especially for uninsured populations,” said Heather Cianfrocco, chief executive officer of Optum Rx, in a release by Business Wire. “By working with Sanofi, we will improve access and lower costs for people who need this life-saving medication.”
Adam Gluck, senior vice president of U.S. corporate affairs at Sanofi said the collaboration supports their ambition to ensure every person in the U.S. living with diabetes can access and afford the insulin they need.
The Optum Store is an integrated healthcare marketplace offering prescriptions, a wide variety of everyday health and wellness products, online doctor visits, and mental health therapy – no insurance required. For prescription medications, Optum Store offers free shipping in all 50 states, auto-refills and seamless integration with virtual care.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 9th 2020In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.
Listen